Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
An alpha-glucosidic linkage is a type of covalent bond (glycosidic bond) that connects two monosaccharides—commonly glucose units—via an alpha-configuration, such as alpha-1,4 or alpha-1,6 linkages. These linkages are fundamental components of carbohydrate polymers like starch (amylose and amylopectin) and glycogen; alpha-1,4 bonds create linear chains while alpha-1,6 bonds form branch points. Enzymes like alpha-glucosidase and amylase catalyze the hydrolysis of alpha-glucosidic linkages, playing a critical role in the digestion and metabolism of carbohydrates. While "alpha-glucosidic linkage" itself is not a therapeutic target, inhibition of its hydrolysis is a central strategy in managing diabetes and metabolic syndrome. If structured target information is needed for a therapeutic target, the correct entity would be Alpha-glucosidase (enzyme), not alpha-glucosidic linkage.
Inhibitors block alpha-glucosidases, reducing the breakdown of dietary polysaccharides to glucose and decreasing postprandial blood glucose elevation. Some drugs may also affect amylase, another enzyme hydrolyzing alpha-glucosidic linkages.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-glucosidic linkage.